These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 25678258)

  • 21. Alectinib: a selective, next-generation ALK inhibitor for treatment of ALK-rearranged non-small-cell lung cancer.
    Santarpia M; Altavilla G; Rosell R
    Expert Rev Respir Med; 2015 Jun; 9(3):255-68. PubMed ID: 25652176
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance.
    Kodama T; Tsukaguchi T; Yoshida M; Kondoh O; Sakamoto H
    Cancer Lett; 2014 Sep; 351(2):215-21. PubMed ID: 24887559
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alectinib for the treatment of ALK-positive stage IV non-small cell lung cancer.
    Wong KM; Noonan S; O'Bryant C; Jimeno A
    Drugs Today (Barc); 2015 Mar; 51(3):161-70. PubMed ID: 25876560
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A safety assessment of crizotinib in the treatment of ALK-positive NSCLC patients.
    Dikopf A; Wood K; Salgia R
    Expert Opin Drug Saf; 2015 Mar; 14(3):485-93. PubMed ID: 25659177
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Successful treatment with ceritinib after crizotinib induced hepatitis.
    Sassier M; Mennecier B; Gschwend A; Rein M; Coquerel A; Humbert X; Alexandre J; Fedrizzi S; Gervais R
    Lung Cancer; 2016 May; 95():15-6. PubMed ID: 27040846
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development.
    Scagliotti G; Stahel RA; Rosell R; Thatcher N; Soria JC
    Eur J Cancer; 2012 May; 48(7):961-73. PubMed ID: 22397764
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transformation to small-cell lung cancer as a mechanism of acquired resistance to crizotinib and alectinib.
    Miyamoto S; Ikushima S; Ono R; Awano N; Kondo K; Furuhata Y; Fukumoto K; Kumasaka T
    Jpn J Clin Oncol; 2016 Feb; 46(2):170-3. PubMed ID: 26613679
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Secondary mutations at I1171 in the ALK gene confer resistance to both Crizotinib and Alectinib.
    Toyokawa G; Hirai F; Inamasu E; Yoshida T; Nosaki K; Takenaka T; Yamaguchi M; Seto T; Takenoyama M; Ichinose Y
    J Thorac Oncol; 2014 Dec; 9(12):e86-7. PubMed ID: 25393798
    [No Abstract]   [Full Text] [Related]  

  • 29. Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer.
    Nishio M; Nakagawa K; Mitsudomi T; Yamamoto N; Tanaka T; Kuriki H; Zeaiter A; Tamura T
    Lung Cancer; 2018 Jul; 121():37-40. PubMed ID: 29858024
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ALK inhibitors: what is the best way to treat patients with ALK+ non-small-cell lung cancer?
    Toyokawa G; Seto T
    Clin Lung Cancer; 2014 Sep; 15(5):313-9. PubMed ID: 24984564
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Crizotinib-induced pancreatic pseudocyst: a novel adverse event.
    Ishida H; Ichikawa W; Sasaki Y
    BMJ Case Rep; 2015 Sep; 2015():. PubMed ID: 26351314
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Successful desensitization of two patients with ALK-positive lung cancer and hypersensitivity to crizotinib.
    Awad MM; Lax TP; Slawski BR; Shaw AT
    J Thorac Oncol; 2014 Nov; 9(11):1726-8. PubMed ID: 25436807
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alectinib Approved for ALK+ Lung Cancer.
    Cancer Discov; 2016 Feb; 6(2):115. PubMed ID: 26739884
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Esophagitis: a novel adverse event of crizotinib in a patient with ALK-positive non-small-cell lung cancer.
    Srivastava N; VanderLaan PA; Kelly CP; Costa DB
    J Thorac Oncol; 2013 Mar; 8(3):e23-4. PubMed ID: 23407563
    [No Abstract]   [Full Text] [Related]  

  • 35. Anaplastic lymphoma kinase rearrangement in lung cancer: its biological and clinical significance.
    Toyokawa G; Seto T
    Respir Investig; 2014 Nov; 52(6):330-8. PubMed ID: 25453376
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Severe acute interstitial lung disease in a patient with anaplastic lymphoma kinase rearrangement-positive non-small cell lung cancer treated with alectinib.
    Yamamoto Y; Okamoto I; Otsubo K; Iwama E; Hamada N; Harada T; Takayama K; Nakanishi Y
    Invest New Drugs; 2015 Oct; 33(5):1148-50. PubMed ID: 26334220
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alectinib: a review of its use in advanced ALK-rearranged non-small cell lung cancer.
    McKeage K
    Drugs; 2015 Jan; 75(1):75-82. PubMed ID: 25428710
    [TBL] [Abstract][Full Text] [Related]  

  • 38. U.S. Food and Drug Administration approval: crizotinib for treatment of advanced or metastatic non-small cell lung cancer that is anaplastic lymphoma kinase positive.
    Malik SM; Maher VE; Bijwaard KE; Becker RL; Zhang L; Tang SW; Song P; Liu Q; Marathe A; Gehrke B; Helms W; Hanner D; Justice R; Pazdur R
    Clin Cancer Res; 2014 Apr; 20(8):2029-34. PubMed ID: 24573551
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases.
    Kodama T; Hasegawa M; Takanashi K; Sakurai Y; Kondoh O; Sakamoto H
    Cancer Chemother Pharmacol; 2014 Nov; 74(5):1023-8. PubMed ID: 25205428
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib.
    Gainor JF; Sherman CA; Willoughby K; Logan J; Kennedy E; Brastianos PK; Chi AS; Shaw AT
    J Thorac Oncol; 2015 Feb; 10(2):232-6. PubMed ID: 25526238
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.